A
grade
Bioengineered acellular tissue engineered vessels versus autogenous fistulae for haemodialysis access: a multicentre, randomised, controlled, phase 3 trial.
Teriparatide (PTH 1-34) · The Lancet. Digital health · 2026 · RCT · Phase 3 · n=242Top journal
ATEV showed superior haemodialysis access outcomes compared to AVF at 1 year, particularly for female patients and those with diabetes and obesity.
Global relative patency of 1·17 (95% CI 1·04-1·31, p=0·0090).